Cathie Wood's ARK Adjusts Portfolio, Sells Palantir and Buys SpaceX

Cathie Wood's ARK Invest has made recent changes to its portfolio, including selling Palantir stock and acquiring shares in SpaceX. This comes as questions arise about the performance of other ARK holdings like CRISPR Therapeutics.

21 Aug, 14:50 — 22 Aug, 00:16

Post Share

Why this matters

Cathie Wood's ARK Invest is a prominent investment firm known for its focus on disruptive innovation. Her portfolio adjustments are closely watched by investors as indicators of market sentiment and potential future trends in technology and growth stocks.

Key entitiesCathie Wood ARK Invest Palantir SpaceX CRISPR Therapeutics

The Story

What 2 sources agree on, dispute, and miss

What sources agree on

Cathie Wood's ARK Invest sold Palantir stock
Cathie Wood's ARK Invest bought SpaceX shares

Key claims2 agreed · 1 unverified

✓

Cathie Wood's ARK Invest sold Palantir stock

agreed·investing-comYahoo

✓

Cathie Wood's ARK Invest bought SpaceX shares

agreed·investing-comYahoo

CRISPR Therapeutics stock is up only 8% this year

unverified·Yahoo

Coverage gaps

Analysis of CRISPR Therapeutics stock performance and its implications for ARK's investment strategy

ReportedYahoo

Missinginvesting-com

The Story

Analyzing sources…

Source Diversity

Moderate (27/100)

2 sources— more sources would strengthen this score15/33

Spectrum spread— 2/5 buckets covered8/33

Far L

Left1

Left (1)

Yahoo

Center1

Center (1)

investing-com

Right

Far R

Geographic diversity— 1 region4/34

US2

ℹAll sources from US region

ℹOnly 2 sources cover this story

Political spectrum

LeftCenterRight

yahoo

investing-com

Outlet rating This story

SourceOutletiGeneral editorial lean of the outletStoryiHow they covered this specific storyToneFactuality

YahoocentercenteranalyticalMostly Factualanalytical focus on investment performance

investing-comcentercenterneutral—factual reporting of portfolio changes

Coverage leans: center

The coverage is largely neutral, focusing on financial transactions and investment performance without significant political framing.

Sources

Showing 2 of 2 sources

YahooMostly Factual11h ago

CRISPR Therapeutics Stock Is Up Only 8% This Year. Is Cathie Wood's Bet on the Gene-Editing Stock Dead Money?

Read full article →

investing-com1h ago

Cathie Wood’s ARK sells Palantir stock, buys SpaceX shares

By Investing.com

Read full article →

Coverage Timeline

First report: Yahoo · 21 Aug, 14:50|Full coverage: 2 · 9h|Window: 9h

Left-leaningCenterRight-leaning

Yahoo21 Aug, 14:50First to report

CRISPR Therapeutics Stock Is Up Only 8% This Year. Is Cathie Wood's Bet on the Gene-Editing Stock Dead Money?

9h later

investing-com22 Aug, 00:16Latest update

Cathie Wood’s ARK sells Palantir stock, buys SpaceX shares

Story evolution

The narrative shifted from a simple reporting of portfolio changes to a more analytical and questioning tone regarding the performance of some of ARK's investments.

Initial ReportingAug 22 morning

Investing.com reports the specific portfolio changes by ARK Invest.

Broader AnalysisAug 21 afternoon

Yahoo Finance expands on ARK's portfolio, questioning the performance of another holding.

PERSPECTA

PERSPECTA

Cathie Wood's ARK Adjusts Portfolio, Sells Palantir and Buys SpaceX

Why this matters

The Story

What sources agree on

Key claims2 agreed · 1 unverified

Coverage gaps

The Story

Source Diversity

Source Diversity

Political spectrum

Sources

CRISPR Therapeutics Stock Is Up Only 8% This Year. Is Cathie Wood's Bet on the Gene-Editing Stock Dead Money?

Cathie Wood’s ARK sells Palantir stock, buys SpaceX shares

Coverage Timeline

CRISPR Therapeutics Stock Is Up Only 8% This Year. Is Cathie Wood's Bet on the Gene-Editing Stock Dead Money?

Cathie Wood’s ARK sells Palantir stock, buys SpaceX shares

Story evolution

Related Stories

TikTok Reaches $400 Million Settlement with US Justice Department Over Child Privacy

US and Canada Race to Avert Tariffs on Metal Imports

Trump Denies Directing Bessent's Bond Market Intervention

Boeing Engineers and Technicians Reject Contract Offer, Authorize Strike

PERSPECTA

Why this matters

Story evolution

The Story

What sources agree on

Key claims2 agreed · 1 unverified

Coverage gaps

Coverage matrix

Political spectrum